Abeona Therapeutics Has Resubmitted Its Biologics License Application To The FDA For Prademagene Zamikeracel (Pz-cel), Its Investigational Autologous Cell-based Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics has resubmitted its Biologics License Application to the FDA for Prademagene Zamikeracel, an investigational gene therapy for Recessive Dystrophic Epidermolysis Bullosa.
October 29, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics has resubmitted its Biologics License Application to the FDA for its gene therapy Prademagene Zamikeracel, which targets Recessive Dystrophic Epidermolysis Bullosa.
The resubmission of the Biologics License Application to the FDA is a significant step for Abeona Therapeutics, as approval could lead to commercialization of their gene therapy. This news is likely to positively impact the stock price in the short term due to the potential for future revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100